MedTrace Logo

Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation

NCT00325390 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2009-03-25

No results posted yet for this study

Summary

To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting).

Conditions

  • Platelet Aggregation Inhibitors
  • NSTEACS

Interventions

DRUG

clopidogrel (SR25990C)

Sponsors & Collaborators

  • Daiichi Pharmaceuticals

    collaborator INDUSTRY

  • Sanofi

    lead INDUSTRY

Principal Investigators

  • Yuko HARADA · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00325390 on ClinicalTrials.gov